<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37150879</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.</ArticleTitle><Pagination><StartPage>2975</StartPage><EndPage>2988</EndPage><MedlinePgn>2975-2988</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awad145</ELocationID><Abstract><AbstractText>TAR DNA-binding protein-43 (TDP-43) accumulation is the primary pathology underlying several neurodegenerative diseases. Charting the progression and heterogeneity of TDP-43 accumulation is necessary to better characterize TDP-43 proteinopathies, but current TDP-43 staging systems are heuristic and assume each syndrome is homogeneous. Here, we use data-driven disease progression modelling to derive a fine-grained empirical staging system for the classification and differentiation of frontotemporal lobar degeneration due to TDP-43 (FTLD-TDP, n = 126), amyotrophic lateral sclerosis (ALS, n = 141) and limbic-predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) with and without Alzheimer's disease (n = 304). The data-driven staging of ALS and FTLD-TDP complement and extend previously described human-defined staging schema for ALS and behavioural variant frontotemporal dementia. In LATE-NC individuals, progression along data-driven stages was positively associated with age, but negatively associated with age in individuals with FTLD-TDP. Using only regional TDP-43 severity, our data driven model distinguished individuals diagnosed with ALS, FTLD-TDP or LATE-NC with a cross-validated accuracy of 85.9%, with misclassifications associated with mixed pathological diagnosis, age and genetic mutations. Adding age and SuStaIn stage to this model increased accuracy to 92.3%. Our model differentiates LATE-NC from FTLD-TDP, though some overlap was observed between late-stage LATE-NC and early-stage FTLD-TDP. We further tested for the presence of subtypes with distinct regional TDP-43 progression patterns within each diagnostic group, identifying two distinct cortical-predominant and brainstem-predominant subtypes within FTLD-TDP and a further two subcortical-predominant and corticolimbic-predominant subtypes within ALS. The FTLD-TDP subtypes exhibited differing proportions of TDP-43 type, while there was a trend for age differing between ALS subtypes. Interestingly, a negative relationship between age and SuStaIn stage was seen in the brainstem/subcortical-predominant subtype of each proteinopathy. No subtypes were observed for the LATE-NC group, despite aggregating individuals with and without Alzheimer's disease and a larger sample size for this group. Overall, we provide an empirical pathological TDP-43 staging system for ALS, FTLD-TDP and LATE-NC, which yielded accurate classification. We further demonstrate that there is substantial heterogeneity amongst ALS and FTLD-TDP progression patterns that warrants further investigation in larger cross-cohort studies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Alexandra L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-7772-781X</Identifier><AffiliationInfo><Affiliation>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Medical Image Computing, Department of Computer Science, University College London, London, WC1V 6LJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Jacob W</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0001-6394-9940</Identifier><AffiliationInfo><Affiliation>Department of Clinical Sciences, SciLifeLab, Lund University, SE-222 42 Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, SE-222 42 Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Penn Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Penn Frontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ossenkoppele</LastName><ForeName>Rik</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, SE-222 42 Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, 1081 HZ Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Amsterdam Neuroscience, Neurodegeneration, 1081 HV Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-5599-5098</Identifier><AffiliationInfo><Affiliation>Penn Frontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Digital Neuropathology Laboratory, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elman</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Penn Frontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VMY</Initials><AffiliationInfo><Affiliation>Penn Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward B</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0002-4589-1180</Identifier><AffiliationInfo><Affiliation>Penn Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansson</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-8467-7286</Identifier><AffiliationInfo><Affiliation>Clinical Memory Research Unit, Lund University, SE-222 42 Lund, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Memory Clinic, Sk&#xe5;ne University Hospital, SE-205 02 Malm&#xf6;, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 MH019112</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG062418</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS109260</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG066597</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG072979</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000723354">limbic-predominant age-related TDP-43 encephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2023 Feb 02;:</RefSource><PMID Version="1">36778217</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2023 Jul 3;146(7):2666-2668</RefSource><PMID Version="1">37224516</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="Y">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">limbic-predominant age-related TDP-43 encephalopathy</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">neuropathological staging</Keyword></KeywordList><CoiStatement>O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche and Siemens. L.E. receives consulting fees from Biogen, PTC Therapeutics, Apellis Pharmaceuticals and Edgewise Therapeutics. D.W. has served as a paid consultant to Eli Lilly, GE Healthcare and Qynapse. He serves on a DSMB for Functional Neuromodulation. He is a site investigator for a clinical trial sponsored by Biogen. R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research &amp; Development, Roche, Quanterix and Optina Diagnostics, and has given lectures in symposia sponsored by GE Healthcare. He is an editorial board member of <i>Alzheimer&#x2019;s Research &amp; Therapy</i> and the <i>European Journal of Nuclear Medicine and Molecular Imaging</i>. All other authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>8</Day><Hour>0</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37150879</ArticleId><ArticleId IdType="pmc">PMC10317181</ArticleId><ArticleId IdType="doi">10.1093/brain/awad145</ArticleId><ArticleId IdType="pii">7156599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, et al. . Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, et al. . Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 2014;127:423&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, et al. . Staging TDP-43 pathology in Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:441&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="pubmed">24240737</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Wilson RS, Chen EY, Bennett DA, Schneider JA. TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD. Neurology. 2017;88:653&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317379</ArticleId><ArticleId IdType="pubmed">28087828</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EJ, Vatsavayai S, Seeley WW. Neuropathology of dementia. In: Miller BL, Boeve BF, eds. The behavioral neurology of dementia. Cambridge University Press; 2016:94&#x2013;122.</Citation></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harb Perspect Med. 2017;7:a024117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren JD, Rohrer JD, Rossor MN. Clinical review. Frontotemporal dementia. BMJ. 2013;347:f4827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3735339</ArticleId><ArticleId IdType="pubmed">23920254</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, et al. . Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. . Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan CT, Wuu J, Rascovsky K, et al. . Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:517&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9448823</ArticleId><ArticleId IdType="pubmed">35253557</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis&#x2014;frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Mackenzie I, Frosch MP, et al. . LATE To the PART-y. Brain. 2019;142:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736234</ArticleId><ArticleId IdType="pubmed">31359030</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, et al. . Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain. 2020;143:2844&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526723</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, et al. . Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137:27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzo R, Oxtoby NP, Young AL, et al. . Prion propagation estimated from brain diffusion MRI is subtype dependent in sporadic Creutzfeldt-Jakob disease. Acta Neuropathol. 2020;140:169&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7360647</ArticleId><ArticleId IdType="pubmed">32535770</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Marinescu RV, Oxtoby NP, et al. . Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with subtype and stage inference. Nat Commun. 2018;9:4273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6189176</ArticleId><ArticleId IdType="pubmed">30323170</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Young AL, Oxtoby NP, et al. . Four distinct trajectories of tau deposition identified in Alzheimer&#x2019;s disease. Nat Med. 2021;27:871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Bocchetta M, Russell LL, et al. . Characterizing the clinical features and atrophy patterns of MAPT-related frontotemporal dementia with disease progression modeling. Neurology. 2021;97:e941&#x2013;e952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8408507</ArticleId><ArticleId IdType="pubmed">34158384</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshaghi A, Young AL, Wijeratne PA, et al. . Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. Nat Commun. 2021;12:2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8024377</ArticleId><ArticleId IdType="pubmed">33824310</ArticleId></ArticleIdList></Reference><Reference><Citation>Young AL, Vogel JW, Aksman LM, et al. . Ordinal SuStaIn: subtype and stage inference for clinical scores, visual ratings, and other ordinal data. Front Artif Intell. 2021;4:613261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8387598</ArticleId><ArticleId IdType="pubmed">34458723</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Van Deerlin VM, Lee EB, et al. . A platform for discovery: the University of Pennsylvania integrated neurodegenerative disease biobank. Alzheimers Dement. 2014;10:477&#x2013;484.e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933464</ArticleId><ArticleId IdType="pubmed">23978324</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Neumann M, Baborie A, et al. . A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. . National institute on aging-Alzheimer&#x2019;s association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksman LM, Wijeratne PA, Oxtoby NP, et al. . Pysustain: a python implementation of the subtype and stage inference algorithm. SoftwareX. 2021;16:100811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8682799</ArticleId><ArticleId IdType="pubmed">34926780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group . Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS Motor phenotype heterogeneity, focality, and spread: Deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M, Conte A, Zollino M. Clinical and genetic heterogeneity of amyotrophic lateral sclerosis. Clin Genet. 2013;83:408&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">23379621</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cairns NJ, Grossman M, et al. . Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129:469&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H, Rohrer JD, Pijnenburg YAL, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Onodera O, et al. . Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions. Acta Neuropathol. 2008;116:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">18481073</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R, Tada M, Shiga A, et al. . Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: evidence for clinico-pathologic subtypes. Acta Neuropathol Commun. 2016;4:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918136</ArticleId><ArticleId IdType="pubmed">27338935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol. 2020;139:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">31501924</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol. 2009;118:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044602</ArticleId><ArticleId IdType="pubmed">19455346</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Geser F, Zhou J, et al. . TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010;75:2204&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013589</ArticleId><ArticleId IdType="pubmed">21172843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, Neumann M, Kwong LK, et al. . Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169:1343&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Baborie A, Pickering-Brown S, et al. . Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 2006;112:539&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668618</ArticleId><ArticleId IdType="pubmed">17021754</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Wiste HJ, Schwarz CG, et al. . Longitudinal tau PET in ageing and Alzheimer&#x2019;s disease. Brain. 2018;141:1517&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5917767</ArticleId><ArticleId IdType="pubmed">29538647</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Early-onset Alzheimer&#x2019;s disease is associated with greater pathologic burden. J Geriatr Psychiatry Neurol. 2007;20:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341768</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Hoshi Y, et al. . Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP-43 pathology. Acta Neuropathol. 2009;117:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923836</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer KR, Foster ZW, Rauf NA, et al. . Neuropathological profile of long-duration amyotrophic lateral sclerosis in military veterans. Brain Pathol. 2020;30:1028&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018169</ArticleId><ArticleId IdType="pubmed">32633852</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve in ageing and Alzheimer&#x2019;s disease. Lancet Neurol. 2012;11:1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3507991</ArticleId><ArticleId IdType="pubmed">23079557</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Arumanayagam AS, Powell SZ, et al. . Patterns of amygdala region pathology in LATE-NC: subtypes that differ with regard to TDP-43 histopathology, genetic risk factors, and comorbid pathologies. Acta Neuropathol. 2022;143:531&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9038848</ArticleId><ArticleId IdType="pubmed">35366087</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Lee EB, Cykowski MD, et al. . LATE-NC staging in routine neuropathologic diagnosis: an update. Acta Neuropathol. 2023;145:159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9849315</ArticleId><ArticleId IdType="pubmed">36512061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>